Contravisory Investment Management Inc. Takes $451,000 Position in LifeStance Health Group, Inc. $LFST

Contravisory Investment Management Inc. acquired a new position in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 42,111 shares of the company’s stock, valued at approximately $451,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in LifeStance Health Group by 21.1% during the 4th quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock valued at $124,608,000 after buying an additional 3,086,506 shares during the last quarter. Silversmith Partners I GP LLC purchased a new stake in shares of LifeStance Health Group in the fourth quarter valued at $100,842,000. Dimensional Fund Advisors LP lifted its position in shares of LifeStance Health Group by 16.4% in the first quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company’s stock valued at $66,038,000 after acquiring an additional 1,461,215 shares in the last quarter. Jennison Associates LLC lifted its position in shares of LifeStance Health Group by 38.5% in the first quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock valued at $65,157,000 after acquiring an additional 2,843,388 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of LifeStance Health Group by 27.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,118,027 shares of the company’s stock valued at $43,071,000 after acquiring an additional 1,324,691 shares during the last quarter. Hedge funds and other institutional investors own 85.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on LFST shares. Canaccord Genuity Group lifted their price objective on LifeStance Health Group from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Barclays upped their target price on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a report on Tuesday, July 14th. BTIG Research lifted their price target on shares of LifeStance Health Group from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Friday. Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $11.62.

LifeStance Health Group Stock Up 9.8%

LFST opened at $11.90 on Tuesday. LifeStance Health Group, Inc. has a 12 month low of $4.39 and a 12 month high of $12.43. The business has a 50-day moving average of $10.02 and a two-hundred day moving average of $8.09. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.38 and a quick ratio of 1.38. The stock has a market capitalization of $4.62 billion, a price-to-earnings ratio of 91.55 and a beta of 1.14.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The business had revenue of $435.35 million for the quarter, compared to analyst estimates of $414.58 million. During the same period in the prior year, the firm posted ($0.01) EPS. The company’s revenue was up 26.1% on a year-over-year basis. On average, research analysts expect that LifeStance Health Group, Inc. will post 0.12 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Robert Bessler sold 894,337 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $10.13, for a total transaction of $9,059,633.81. Following the completion of the transaction, the director owned 539,763 shares of the company’s stock, valued at approximately $5,467,799.19. This represents a 62.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 3.50% of the company’s stock.

LifeStance Health Group Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.